Diabetes mellitus in a cohort of patients with acromegaly.

Objectives: To evaluate the presence of diabetes mellitus (DM) in a cohort of patients with acromegaly.

Methods: This was a cross sectional study.

Results: Fifty-eight acromegalic patients were assessed.

Hypertension-related factors in patients with active and inactive acromegaly.

Introduction: There are several complications of the cardiovascular system caused by acromegaly, especially hypertension.

Objectives: To evaluate hypertension characteristics in patients with cured/controlled acromegaly and with the active disease.

Patients And Methods: Cross-sectional study of the follow-up of forty-four patients with acromegaly submitted to clinical evaluation, laboratory tests and cardiac ultrasound.

Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.

Treatment with rosiglitazone has been associated with severe paradoxical HDL-c reductions. To our knowledge, there are very few reports of this reaction occurring when patients are treated without the combination of a fibrate. A case of severe HDL-c lowering in a patient treated with rosiglitazone without a fibrate is presented.

[Cardiovascular disturbances in acromegaly].

Acromegaly causes a number of disorders in the cardiovascular system, resulting from chronic exposure to high levels of GH and IGF-1. Such disorders are the main responsible for increased mortality rates among acromegalic patients. Among several forms of cardiovascular impairment is acromegalic cardiomyopathy, an entity that is initially characterized by a hyperdynamic state, followed by concentric left ventricular hypertrophy and diastolic dysfunction due to relaxation deficit, culminating in systolic dysfunction and sometimes heart failure.